CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 200 enrolled
Drug / intervention
Favipiravir +1 moredrug
Likely dose
Favipiravir 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04542694
NCT04542694Phase 3Completed
CompareCT.gov

Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19

Promomed, LLC·interventional·Posted Sep 9, 2020·Updated Nov 5, 2020

In Brief

A Phase 3 clinical trial evaluating Favipiravir and Standard of care for COVID-19. Completed, enrolled 200 participants across 5 sites.

Detailed Summary

This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedSep 9, 2020
Enrollment StartMay 21, 2020
Primary CompletionAug 10, 2020
Study CompletionAug 20, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.8 years ago

Interventions

Favipiravirdrug

200 mg coated tablets

Standard of caredrug

Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator. Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc.